enow.com Web Search

Search results

  1. Results from the WOW.Com Content Network
  2. A total of 599 patient data entry forms out of 600 with an equal distribution of genders (49% men, 51% women) and a mean age of 57 years (SD 19 years) were available for analysis. An open approach ...

  3. The aim of this study was to determine the current practice of surgeons in terms of access to and closure of the abdominal cavity in elective open surgery. Methods: Twelve surgical departments of ...

  4. Twelve of the 25 participating centres of the INSECT-Trial group agreed in contribution to data acquisition (see acknowledgment). The local ethics committees of participating centres granted ...

  5. [17,20,22,23] The concerns of using a suture-mediated device in these patients are due to (1) ... A subcutaneous suture is placed, and a subcuticular stitch closes the small stab wound. A Steri ...

  6. English Edition. Medscape. English; Deutsch; Español; Français; Português; Univadis

  7. In a randomized controlled trial, there were 57% fewer wound complications after cesarean section with suture closure of the incision compared with staple closure. News & Perspective Drugs & Diseases

  8. Commentary on a study assessing wound complications with subcuticular sutures vs staples for skin closure after open gastrointestinal surgery, published in September 2013 in the Lancet.

  9. Manual compression, use of a temporary subcutaneous suture, or placement of a percutaneous closure device may be used to close the femoral vein access site. Figure 2 shows echocardiographic still ...

  10. This study attempted to determine the current practice of surgeons regarding access to and closure of the abdominal cavity in elective open surgery.

  11. FDA Okays Subcutaneous Ocrelizumab for MS - Medscape

    www.medscape.com/viewarticle/fda-okays-subcutaneous-ocrelizumab-ms-2024a1000gp3

    September 13, 2024. 0. The US Food and Drug Administration (FDA) has approved a subcutaneous formulation of the anti-CD20 antibody ocrelizumab (Ocrevus Zunovo, Genentech) for the treatment of ...